Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
AptarGroup (ATR) Delivers Q3 Earnings Beat Despite One-Time Hits

AptarGroup (ATR) Delivers Q3 Earnings Beat Despite One-Time Hits

Key Takeaways

  • AptarGroup reported third quarter 2026 adjusted earnings per share (EPS) of $1.52, beating the analyst consensus estimate of $1.47 by $0.05.
  • Revenue came in at approximately $1.02 billion, topping consensus expectations of roughly $981 million and rising about 6% year over year.
  • Reported (GAAP) diluted EPS fell sharply to $0.51, weighed down by a $58 million loss tied to the Russia deconsolidation and non-ordinary-course litigation costs.
  • The company issued fourth quarter 2026 adjusted EPS guidance of $1.39 to $1.47, bracketing the analyst consensus of $1.41.
  • Growth was broad-based across all three segments — Pharma, Beauty, and Closures — with double-digit core sales growth in Closures.
  • For deeper context, explore AptarGroup's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
  • You can also discover market-moving signals and automated strategies through Tickeron's Trending AI Robots.

Why These Results Matter

AptarGroup sits at the intersection of healthcare and consumer packaging, supplying drug delivery and dispensing technologies to pharmaceutical, beauty, and food-and-beverage customers globally. The third-quarter report therefore provides a useful window into prescription drug demand, new product activity in injectables and central nervous system therapies, and broader consumer spending trends. It also represents the first full quarter under new CEO Gael Touya, so the tone of management commentary and the forward guidance drew particular attention. The sizable gap between adjusted and GAAP earnings underscores how one-time items, such as the Russia deconsolidation loss and litigation costs, can obscure underlying operational performance even when core sales continue to expand.

Breaking Down the Quarter

AptarGroup posted third quarter 2026 revenue of roughly $1.02 billion, up about 6% from $961.1 million a year earlier and ahead of the consensus estimate near $981 million. Adjusted EPS of $1.52 cleared the $1.47 consensus, reflecting solid operational results across the three segments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

On a GAAP basis the picture looked weaker. Diluted EPS fell to $0.51, a decline of about 73% year over year, while net income attributable to common shareholders dropped to roughly $32.6 million. The main drivers were a $58 million loss on the Russia deconsolidation and other special items tied to non-ordinary-course litigation, including the ongoing disputes with ARS Pharmaceuticals over trade-secret claims.

Operating income eased 1.4% to $135.0 million, while gross profit rose 2.7% to $372.9 million. Management guided fourth quarter 2026 adjusted EPS to a range of $1.39 to $1.47, which brackets the analyst consensus of $1.41.

Market Reaction

Investor sentiment appeared to reflect the contrast between clean top-line and adjusted-EPS beats and a noisier GAAP result. The revenue and adjusted-earnings outperformance pointed to healthy underlying demand, especially in pharma and beverage-dispensing innovation, while the Russia charge and litigation costs raised questions about earnings quality. Fourth-quarter guidance landed roughly in line with expectations, offering neither a strong catalyst nor a clear negative surprise. Pre-report sentiment had been cautious, and the mixed headline numbers left the market balancing operational momentum against the impact of non-recurring items.

Forward Outlook

Investors will want to track whether AptarGroup can maintain momentum in the Pharma segment, which showed notable growth in central nervous system therapies, pulmonary treatments, injectables, and consumer healthcare. Management continues to stress converting its pharma pipeline into commercial launches, and the pace of those conversions should remain a key driver.

The Closures segment also merits attention after delivering double-digit core sales growth fueled by beverage-dispensing innovation. Sustaining that pace will hinge on customer adoption and further product rollouts.

Cost discipline and margin trends are additional points to watch. Although gross profit expanded, operating income dipped slightly, so investors will look for one-time litigation and deconsolidation items to fade in coming quarters.

Finally, under new CEO Gael Touya, attention will turn to any shifts in capital allocation and execution priorities, including the focus on deeper customer relationships, faster innovation, and greater consistency that could influence both organic growth and potential acquisitions.

Using AI Tools in My Analysis

When evaluating companies like ATR, I often turn to Tickeron’s AI Screener to quickly compare fundamentals, technical patterns, and peer performance across the packaging and pharma supply space. It helps surface relevant setups without spending hours on manual filtering, which keeps my research process efficient.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ATR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for ATR turns negative, indicating new downward trend

ATR saw its Momentum Indicator move below the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 43 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 52%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ATR moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 10 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 30%.

The Moving Average Convergence Divergence Histogram (MACD) for ATR turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 21 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 35%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.

ATR broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 58 cases where ATR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.

ATR moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ATR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.

The 50-day moving average for ATR moved above the 200-day moving average on November 10, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATR advanced for three days, in 181 of 332 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.

The Aroon Indicator entered an Uptrend today. In 112 of 222 cases where ATR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ATR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.447) is normal, around the industry mean (4.964). P/E Ratio (25.446) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (2.595) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.006) among similar stocks. P/S Ratio (2.072) is also within normal values, averaging (56.876).

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of consumer dispensing systems

Industry PharmaceuticalsOther

Industry
Containers Or Packaging
Address
265 Exchange Drive
Phone
+1 815 477-0424
Employees
14000
Web
https://www.aptar.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.